Drug Search Results
More Filters [+]

AZD-0171

Alternative Names: azd-0171, azd 0171, azd0171, MSC-1
Latest Update: 2024-02-28
Latest Update Note: Clinical Trial Update

Product Description

AZD0171 is a monoclonal antibody that binds to LIF and prevents signaling through LIF receptor. A murine surrogate of AZD0171 (mAZD0171) was generated and tested in vivo using three syngeneic murine cancer models, and AZD0171 was tested in patient derived xenograft models. (Sourced from: https://aacrjournals.org/cancerres/article/82/12_Supplement/1293/700918/Abstract-1293-AZD0171-anti-LIF-combines#:~:text=AZD0171%20is%20a%20monoclonal%20antibody,in%20patient%20derived%20xenograft%20models.)

Mechanisms of Action: WEE1 Blocker

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD-0171

Countries in Clinic: Canada, Korea, Spain, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Adenocarcinoma|Leukemia|Pancreatic Cancer|Pancreatic Ductal Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

D8151C00001

P2

Active, not recruiting

Pancreatic Ductal Carcinoma|Leukemia|Pancreatic Cancer|Adenocarcinoma

2024-10-07

49%

2021-002040-78

P2

Active, not recruiting

Pancreatic Cancer|Adenocarcinoma|Pancreatic Ductal Carcinoma

2023-12-05

Recent News Events